Allorion Therapeutics partners with AstraZeneca for global license agreement to develop new lung cancer treatment; AstraZeneca will license Allorion's L858R EGFR inhibitor, with Allorion set to receive up to US$540.0M in payments and worldwide royalties

Sample article from our Health Care Sector

NATICK, Massachussetts , January 2, 2024 (press release) –

Allorion Therapeutics ("Allorion"), a US and China -based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally. Allorion is eligible to receive upfront and near-term payments of up to $40 million , and additional development and commercial milestone payments of over $500 million , as well as tiered royalties on net sales worldwide.

Fang Li, PhD., Cofounder and Chief Scientific Officer of Allorion remarked, "Allorion's EGFR L858R allosteric inhibitor is designed to address mechanisms of resistance to current EGFR inhibitors and has the potential to enhance their activity, when used in combination. We are excited to enter into this agreement with AstraZeneca , a global leader in this field, to advance our EGFR inhibitor into the clinic and explore potential combinations with other EGFR targeting molecules such as Tagrisso."

Allorion Therapeutics
Allorion Therapeutics is a biotechnology company that focuses on creating new small molecule drugs for treating cancer and autoimmune diseases. The company has a team of experienced drug discovery and development professionals who can identify new drugs with unique mechanisms of actions and develop innovative data and screening platforms for long-term success. Allorion Therapeutics aims to advance new drugs with high clinical relevance.

Media Contact
media@alloriontx.com

 View original content to download multimedia:https://www.prnewswire.com/news-releases/allorion-therapeutics-announces-exclusive-option-and-global-license-agreement-for-novel-preclinical-stage-egfr-l858r-allosteric-inhibitor-program-with-astrazeneca-302023562.html

SOURCE Allorion Therapeutics

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.